s
s
s
Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug ocrelizumab (Ocrevus) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies specific to ocrelizumab
Specificity Binding Type |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Ocrelizumab Inhibitory Type 1 |
HCA399 |
AbD47395ia |
hIgG1 |
25.6 |
ADA control |
|
HCA400 |
AbD50641ia |
hIgG1 |
<0.001 |
ADA control |
||
HCA401 |
AbD50989ia |
hIgG1 |
0.06 |
ADA control |
||
TZA044 |
AbD50641ad |
Fab-F-Spy2-H1 |
<0.001 |
PK bridging ELISA (capture) |
||
TZA045 |
AbD50651ad |
Fab-F-Spy2-H1 |
<0.001 |
PK bridging ELISA (detection) |
||
TZA045P |
AbD50651pap |
Fab2-FH-X22-HRP2 |
<0.001 |
PK bridging ELISA (detection) |
* Affinity measured in the monovalent Fab format
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
2 Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher
Type 1 anti-ocrelizumab antibodies inhibit the binding of the drug ocrelizumab to its target, the B cell surface marker CD20. They are ideal for the development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Fig. 1. Ocrelizumab PK bridging ELISA using antibodies TZA044 and TZA045P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.
Fig. 2. Ocrelizumab ADA bridging ELISA using antibody HCA399, HCA400, and HCA401
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.